Explore Q1 2025's biotech stock moves, from CervoMed's 300% surge to Septerna's struggles. Click for my review of the quarter ...
Novo Nordisk has experienced a 50% drop due to potential tariffs and recent clinical trial results. Read why I rate NVO stock a strong buy right now.
Novo Nordisk has defended disappointing trial results for its much-hyped next generation obesity drug candidate CagriSema, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback